Scientific deep-dive

Lifestyle Plus the Drug

Across 98,261 people, taking a GLP-1 and keeping six to eight healthy habits meant 43% fewer cardiovascular events than three or fewer habits and no drug. The two figures people will compare cannot be compared.

By Nora Bissett · Pricing Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
5 min read·1 citations

The tiresome argument about whether people should “just eat better instead” has an answer now, from 98,261 people followed across 632,543 person-years. Doing both beat doing either. People taking a GLP-1 and keeping six to eight healthy habits had 43% fewer major cardiovascular events than people with three or fewer habits and no drug.[1]

What was measured

Adjusted hazard ratios for major adverse cardiovascular events. Note that the comparison groups differ between rows.
ComparisonHazard ratio
All eight low-risk lifestyle habits vs one or fewer0.40 (95% CI 0.30–0.54)
GLP-1 users vs non-users0.84 (95% CI 0.76–0.92)
GLP-1 plus six to eight habits vs three or fewer habits and no GLP-10.57 (95% CI 0.46–0.71)

The authors’ conclusion is that combining lifestyle change with pharmacotherapy produced a greater reduction than either approach alone.[1]

The comparison you cannot make from this table

It is tempting to set 0.40 against 0.84 and conclude lifestyle is roughly four times more powerful than the drug. That comparison is not available, and it is the misreading this study will be used for.

The rows are different contrasts. One compares the extremes of an eight-point gradient; the other compares taking a drug against not taking it.

“Eight habits versus one or fewer” contrasts the healthiest people in the dataset against the least healthy across a wide range of behaviors. “GLP-1 user versus non-user” is a single yes-or-no. Those produce numbers that cannot be ranked against each other, any more than you could compare the effect of “the top versus bottom of a scale” with “on versus off a switch”.

There is a second problem specific to lifestyle findings in observational data. Adhering to eight healthy habits is not a randomly distributed trait — it correlates with income, housing, working hours, disability, and every other advantage that independently predicts cardiovascular outcomes. Adjustment helps and does not remove it.

What the finding does support

  • The two are not alternatives. This is the useful part, and it is the opposite of how the choice is usually framed publicly.
  • Taking the drug does not make lifestyle irrelevant. The combined group did better than drug users generally.
  • The drug is not a substitute for the habits, and the habits are not a reason to refuse the drug. Both directions of that sentence are supported here.
  • It is consistent with the randomized picture. In a four-arm trial we covered in exercise plus a GLP-1, the drug alone did nothing for physical fitness while exercise did, and the combination did most.
This is an observational study in a Veterans Affairs population, so it establishes association rather than causation, and the population is not representative — predominantly older and predominantly male. The direction is consistent with everything else, which is why it is worth citing, and it is not a trial.

Frequently Asked Questions

References

  1. 1.Nguyen XT, Li Y, Czernichow S, et al. Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes The Lancet Diabetes & Endocrinology. 2026. PMID: 41763234.

Exercise Plus a GLP-1: What Each One Actually Changes

In a four-arm randomized trial, the drug alone produced no improvement in physical fitness. Exercise alone did. Both together did most — and the strength result needs reading carefully.

6 min read

Muscle Loss: Drug Versus Dieting

Across 20 trials in 15,782 people, the share of weight lost as lean mass was the same on incretin drugs as on dieting (p=0.42). Adding resistance training cut it from about a quarter to 17.5%.

6 min read

The Cardiovascular Cost of Stopping

A review argues that weight and blood sugar fluctuation are themselves cardiovascular risk factors, and that these drugs do not stabilize arteries the way statins do. It also says few data exist on hard outcomes after stopping.

5 min read

GLP-1s and Atrial Fibrillation: Reading a 42% Headline

A meta-analysis of ten trials in 12,651 patients found a 42% lower risk of new atrial fibrillation on semaglutide. None of those trials was designed to measure it, and the absolute numbers were never published.

6 min read

Two Studies, One Comparison, Two Answers

One real-world study found no cardiovascular difference between the two drugs. Another found semaglutide 29% better. Working out why they disagree is more useful than either answer.

6 min read

Beyond BMI: Who Actually Needs Treatment

Among people all above BMI 27, ten-year cardiovascular mortality ranged from 5.7% to 0.1%. And in trial participants, weight loss was similar across risk groups — so treating by risk costs nothing in effectiveness.

6 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.9

Oak

Semaglutide at $119/month, 37% under the register median

6.5

Direct Meds

Compounded semaglutide at $249/month

7.7

Try Ageless

Semaglutide at $119/month, 37% under the register median